Tufts Medical Center, Boston, MA, USA.
J Oncol Pharm Pract. 2021 Oct;27(7):1569-1577. doi: 10.1177/1078155220960809. Epub 2020 Oct 6.
Although oral anticancer medications (OAM) provide opportunity for treatment at home, challenges include prescription filling, monitoring side effects, safe handling, and adherence. We assessed understanding of and adherence to OAM in vulnerable patients.
This 2018 pilot study defined vulnerable patients based on Chinese language, older age (≥65 years), and subsidized insurance. All participants had a cancer diagnosis and were taking an OAM filled through the hospital's specialty pharmacy. Participants reported on OAM taking (days per week, times per day, special instructions) and handling (handling, storage, disposal). The specialty pharmacist classified patient-reported responses about OAM taking and handling as adequate or inadequate. OAM regimens were classified by complexity.
Of 61 eligible patients, 55 participated. Mean age was 68 years (standard deviation [SD] = 12) and 53% were female. Patient subgroups were: 27% Chinese, 64% ≥65 years, and 9% subsidized insurance. Forty-nine percent were on frontline therapy and median time on OAM was 1 year (Quartile 1 = 0.4, Quartile 3 = 1.7). Adequacy of OAM taking (30%) and handling (15%) were low; 15% had adequacy in both. Adequacy of OAM taking and handling did not vary by patient subgroup or regimen complexity. Mean patient-reported adherence was high (5.4, SD = 1, possible range 1-6) and did not vary by adequacy of OAM taking or handling.
Understanding of OAM taking and handling in this group of vulnerable patients was low and did not align with patient-reported adherence. Future interventions should ensure that patients understand how to safely take and handle OAM, thereby optimizing their therapeutic potential.
尽管口服抗癌药物(OAM)提供了在家治疗的机会,但仍存在挑战,包括处方填写、监测副作用、安全处理和用药依从性。我们评估了脆弱患者对 OAM 的理解和依从性。
这项 2018 年的试点研究根据中文、年龄较大(≥65 岁)和补贴保险来定义脆弱患者。所有参与者均被诊断患有癌症,并正在使用医院专科药房开具的 OAM。参与者报告了 OAM 的服用(每周几天、每天几次、特殊说明)和处理(处理、储存、处置)情况。专科药剂师将患者报告的 OAM 服用和处理情况归类为充分或不充分。OAM 方案按复杂性进行分类。
在 61 名符合条件的患者中,有 55 名参与了研究。平均年龄为 68 岁(标准差[SD] = 12),53%为女性。患者亚组包括:27%为中文患者,64%年龄≥65 岁,9%为补贴保险患者。49%的患者正在接受一线治疗,OAM 的中位使用时间为 1 年(四分位间距 1 = 0.4,四分位间距 3 = 1.7)。OAM 服用(30%)和处理(15%)的充分性较低;15%的患者在这两方面都充分。OAM 服用和处理的充分性不因患者亚组或方案复杂性而异。患者报告的依从性均值较高(5.4,SD = 1,可能范围 1-6),且不因 OAM 服用或处理的充分性而异。
在这群脆弱患者中,对 OAM 服用和处理的理解较低,与患者报告的依从性不一致。未来的干预措施应确保患者了解如何安全地服用和处理 OAM,从而最大限度地发挥其治疗潜力。